Cadila Healthcare Ltd receives EIR for formulations facility at Baddi

Cadila Healthcare Ltd has announced that its formulations manufacturing facility located at Baddi, India has received an Establishment Inspection Report (EIR). The EIR report stated that the classification of the facility is 'No Action Indicated (NAI)'. The USFDA had conducted an inspection at the facility from 2nd to 9th March, 2020. The audit had ended with nil observations. FDA has concluded that this inspection is 'closed' under 21 CFR 20.64(d)(3).

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.338.05 as compared to the previous close of Rs. 337.8. The total number of shares traded during the day was 91204 in over 1750 trades.

The stock hit an intraday high of Rs. 342.85 and intraday low of 333.6. The net turnover during the day was Rs. 30915983.

Source : Equity Bulls

Keywords